Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes
Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes
This trial is conducted in Europe, Oceania, Africa, Asia and South America. This trial is designed to show the effect of treatment with liraglutide when adding to existing metformin therapy and to compare it with the effects of metformin monotherapy and combination therapy of metformin and glimepiride. Two trial periods: A 6 month (26 weeks) randomised, double-blinded period followed by an 18 months open-label extension, in total 2 years (104 weeks).
Inclusion Criteria:
Exclusion Criteria:
Ciudad Autonoma de Bs As, C1405CWB, Argentina
Ciudad Autónoma de Bs As, C1426ABP, Argentina
Ciudad Autónoma de BsAs, C1406FWY, Argentina
East Ringwood, Victoria 3135, Australia
Auckland, Australia
Christchurch, 8011, Australia
Århus C, 8000, Denmark
Kutenholz-Mulsum, 27449, Germany
Pohlheim, 35415, Germany
Saint Ingbert, 66386, Germany
Hyderabad, Andhra Pradesh 500082, India
Bekkestua, 1357, Norway
Berkshire, RG7 3SQ, United Kingdom